CoChat

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Abstract Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS) in patients with aggressive NHL treated with cyclophosphamide and fludarabine lymphodepletion followed by 2 × 106 CD19-directed CAR T cells/kg. The best overall response rate was 51%, with 40% of patients achieving complete remission. The median PFS of patients with aggressive NHL who achieved complete remission was 20.0 months (median follow-up, 26.9 months). Multivariable analysis of clinical and treatment characteristics, serum biomarkers, and CAR T-cell manufacturing and pharmacokinetic data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable cytokine profile, defined as serum day 0 monocyte chemoattractant protein-1 (MCP-1) and peak interleukin-7 (IL-7) concentrations above the median, were associated with better PFS. MCP-1 and IL-7 concentrations increased after lymphodepletion, and higher intensity of cyclophosphamide and fludarabine lymphodepletion was associated with higher probability of a favorable cytokine profile. PFS was superior in patients who received high-intensity lymphodepletion and achieved a favorable cytokine profile compared with those who received the same intensity of lymphodepletion without achieving a favorable cytokine profile. Even in high-risk patients with pre-lymphodepletion serum LDH levels above normal, a favorable cytokine profile after lymphodepletion was associated with a low risk of a PFS event. Strategies to augment the cytokine response to lymphodepletion could be tested in future studies of CD19 CAR T-cell immunotherapy for aggressive B-cell NHL. This trial was registered at www.clinicaltrials.gov as #NCT01865617.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2018-11-887067

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 355

Metadata

Authors
Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Acharya, U. H., Cassaday, R. D., Chapuis, A. G., Dhawale, T. M., Hendrie, P. C., Kiem, H.-P., Lynch, R. C., Ramos, J., Shadman, M., Till, B. G., Riddell, S. R., Maloney, D. G., & Turtle, C. J.
Affiliations
  • Fred Hutch Cancer Center (US)
  • University of British Columbia (CA)
  • Juno Therapeutics (United States) (US)
  • Department of Laboratory Medicine and
  • University of Washington (US)
Venue
Blood
Published
2019-04-25
Volume
133
Issue
17
Pages
1876-1887
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2917127842
Cited by
355
References
41
Citations by year
2026: 30 · 2025: 46 · 2024: 44 · 2023: 55 · 2022: 57 · 2021: 66 · 2020: 42 · 2019: 15
FWCI
18.81
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fred Hutchinson Cancer Research Center
  • Celgene
  • University of British Columbia
  • National Institutes of Health (1s10od020069-01, CA15704, DK56465)
  • Juno Therapeutics
  • National Cancer Institute (P30CA 15704, CA136551, R01CA136551, CA 15704+, P30CA015704)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK56465, DK 56465, P30DK056465, P30 CA15704, CA15704, U54DK106829)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD19 CAR T-cell therapy, aggressive non-Hodgkin lymphoma, B-cell lymphoma, lymphocyte depletion, progression-free survival, lactate dehydrogenase, MCP-1, IL-7, cytokine profile, prognostic factors, complete remission, CAR T cell manufacturing
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Cyclophosphamide, Female, Follow-Up Studies, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Prognosis, Receptors, Antigen, T-Cell, Vidarabine, Survival Rate, Antigens, CD19, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. https://app.cochat.ai/papers/10.1182/blood-2018-11-887067
The paper
Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Acharya, U. H., Cassaday, R. D., Chapuis, A. G., Dhawale, T. M., Hendrie, P. C., Kiem, H.-P., . . . Turtle, C. J. (2019). The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. https://doi.org/10.1182/blood-2018-11-887067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.